5-methoxy-6-methyl-2-aminoindan has been researched along with mdl 100907 in 1 studies
| Studies (5-methoxy-6-methyl-2-aminoindan) | Trials (5-methoxy-6-methyl-2-aminoindan) | Recent Studies (post-2010) (5-methoxy-6-methyl-2-aminoindan) | Studies (mdl 100907) | Trials (mdl 100907) | Recent Studies (post-2010) (mdl 100907) |
|---|---|---|---|---|---|
| 13 | 0 | 0 | 1,241 | 65 | 539 |
| Protein | Taxonomy | 5-methoxy-6-methyl-2-aminoindan (IC50) | mdl 100907 (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0048 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marona-Lewicka, D; Nichols, DE; Thisted, RA | 1 |
1 other study(ies) available for 5-methoxy-6-methyl-2-aminoindan and mdl 100907
| Article | Year |
|---|---|
Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
Topics: Amphetamine; Amphetamines; Animals; Apomorphine; Behavior, Animal; Cues; Discrimination Learning; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Fluorobenzenes; Hallucinogens; Haloperidol; Indans; Injections, Intraperitoneal; Lysergic Acid Diethylamide; Male; Piperidines; Psychotic Disorders; Quinolines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists; Time Factors | 2005 |